Antibodies Against Astrocyte M1 and M2 Muscarinic Cholinoceptor from Schizophrenic Patients' Sera

GLIA

Volumn 45, Issue 2, 2004, Pages 144-154

  Borda, Tania ^a   Gomez, Ricardo ^a,b   Berría, Maria I ^a,b   Sterin Borda, Leonor ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

Astrocyte cells; Autoantibodies; Binding assay; Dot blot; ELISA procedure; Flow cytometry; Muscarinic acetylcholine receptors; Schizophrenia

Indexed keywords

AUTOANTIBODY; CYCLIC AMP; IMMUNOGLOBULIN G; INOSITOL PHOSPHATE; MEMBRANE ANTIGEN; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTIBODY; MUSCARINIC M2 RECEPTOR; MUSCARINIC M2 RECEPTOR ANTIBODY; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ACETYLCHOLINE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; ASTROCYTE; AUTOIMMUNITY; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DOT HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOFLUORESCENCE; LIGAND BINDING; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; SEQUENCE HOMOLOGY; ANIMAL; ANTIBODY SPECIFICITY; BINDING COMPETITION; BLOOD; BRAIN; CELL CULTURE; CELL MEMBRANE; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SYNAPTIC TRANSMISSION; WISTAR RAT;

ACETYLCHOLINE; ADULT; ANIMALS; ANTIBODY SPECIFICITY; ASTROCYTES; AUTOANTIBODIES; BINDING, COMPETITIVE; BRAIN; CELL MEMBRANE; CELLS, CULTURED; CYCLIC AMP; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOGLOBULIN G; INOSITOL PHOSPHATES; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 1042302902     PISSN: 08941491     EISSN: None     Source Type: Journal    
DOI: 10.1002/glia.10312     Document Type: Article

References (59)

1. American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association.
2. Andreasen NC, Rezai K, Alliger R, Swayze VW II, Flaum M, Kirchner P, Cohen G, O'Leary DS. 1992. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia: assesment with xenon 133 single-photon emission computed tomography and the tower of London. Arch Gen Psychiatry 49:943-958.
3. Aschauer H, Urch A, Resch F. 1987. Natural immunity in schizophrenia. Ann NY Acad Sci USA 496:743-744.
4. Berria MI, Lascano EF. 1985. Astrocytes differentiation induced by Junin virus in rat brain cell cultures. Acta Neuropathol 66:233-238.
5. Borda T, Genaro A, Sterin-Borda L, Cremaschi G. 1998. Involvement of endogenous nitric oxide signalling system in brain muscarinic acetylcholine receptor activation. J Neural Transm 105:193-204.
6. 1 muscarinic acetylcholine receptor activation. Int J Cardiol 70:23-29.
7. Borda T, Perez Rivera R, Joensen L, Gomez R, Sterin-Borda L. 2002. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 168:3667-3674.
8. Buchsbaum M. 1990. The frontal lobes, basal ganglia and temporal lobes as sites of schizophrenia. Schizophr Bull 16:379-389.
9. Bymaster F, Shannon H, Rasmussen K, DeLapp NW, ward JS, Calligaro DO, Mitch CH, Whitesitt C, Ludvigsen TS, Sheardown M, Swedberg M, Rasmussen T, Olesen PH, Jeppesen L, Saneberg P, Fink-Jensen A. 1999. Potential role of muscarinic receptors in schizophrenia. Life Sci 64:527-534.
10. Carlsson A. 1978. Antipsychotic drugs, neurotransmitters ans schizophrenia. Am J Psychiatry 135:165-169.
11. Chengappa KN, Yang Z, Schurin G, Farooqui S, Rabin B, Ganguli R. 1993. Antibodies to D2-receptor in neuroleptic naive schizophrenic patients. Biol Psychiatry 33:97A.
12. Colburn KK, Green LM, Wong AK. 2001. Circulating antibodies to guanosine in systemic lupus erythematossus: correlation with nephritis and polyserositis by acute and longitudinal analyses. Lupus 10:4-10.
13. Colombo C, Abbruzzese M, Livian S, Scotti G, Locatelli M, Bonfanti A, Scarone S. 1993. Memory functions and temporal-limbic morphology in schizophrenia. Psychiatr Res Neuroimag 50:45-56.
14. Cotter DR, Pariante CM, Everrall IP. 2001. Gial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 55:585-595.
15. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2000. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381.
16. DeLisi LE, King AC, Targum S. 1995. Serum immunoglobulin concentrations in patients admitted to an acute psychiatric inpatient service. Br J Psychiatry 145:661-666.
17. Eng LF, Guirnikar RS, Lee YL. 2000. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 64:582-589.
18. 2b immunoglobulins from mouse serum using protein A-Sepharose. Biochemistry 15:429-436.
19. Falkai P, Honer WG, David S, Bogerts B, Majtenyi C, Bayer TA. 1999. No evidence for astrogliosis in brains of schizophrenic patients: a post-mortem study. Neuropathiol Appl Neurobiol 25:48-53.
20. Fessel WJ. 1963. The antibrain factors in psychiatric patients' sera. Arch Gen Psychiatry 8:110-117.
21. 2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 91:1964-1968.
22. Galinowski A, Barbouche R, Truffinet P, Louzir H, Poirier MF, Bouvet O, Loo H, Avrameas S. 1992. Natural antibodies in schizophrenia. Acta Psychiatr Scand 85:240-242.
23. Ganguli R, Rabin BS, Belle SH. 1989. Decreased interleukin-2 production in schizophrenic patients. Biol Psychiatry 26:427-430.
24. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar UL, Rabin BS. 1993. Autoimmunity in schizophrenia: a review of recent findings. Ann Med 25:489-496.
25. Goin JC, Perez Leiros C, Borda E, Sterin-Borda L. 1997. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 10:77-83.
26. Goldberg TE, Gold JM, Braff DL. 1991. Neuropsychological functioning and time-linked information processing in schizophrenia. Am Psychiatr Press Rev Psychiatry. 10:60-78.
27. Grafman J, Holyak KJ, Boller F, editors. 1995. Structure and functions of the human prefrontal cortex: annals of the New York Academy of Science, vol. 769. New York: New York Academy of Science.
28. Heath RG, McCarron KL, O'Neil CE. 1990. Antiseptal brain antibody in IgG of schizophrenic patients. Biol Psychiatry 27:681-682.
29. Henn FA. 1978. Dopamine and schizophrenia. A therapy revisited and revised. Lancet 2:292-295.
30. Henneberg AE, Horter S, Ruffer S. 1999. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res 14:15-22.
31. Hinze-Selch, D, Becker EW, Stein GM, Berg PA, Mullington J, Holsboer F, Hirata-Hibi M, Higashi S, Tachibana T, Watanake N. 1982. Stimulated lymphocytes in schizophrenia. Arch Gen Psychiatry 39:82-87.
32. Holden RJ, Pakula IS. 1995. Immunological influences in attention-deficit disorder and schizophrenia: is there a link between these two conditions? Med Hypotheses 45:575-587.
33. Hosli E, Hosli L. 1988. Autoradiographic localization of binding sites for muscarinic and nicotinic agonists and antagonists on cultured astrocyte. Exp Brain Res 71:450-454.
34. Hosli E, Hosli L. 2000. Colocalization of neurotransmitter receptors on astrocytes in explant cultures of rat CNS. Neurochem Int 36:301-311.
35. Kelly RH, Ganguli R, Rabin BS. 1987. Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia. Biol Psychiatry 22:1488-1491.
36. Lehmann-Facius H. 1937. Uber die Liquordiagnose der Schizophrenien. Klin Wochenschr 16:1646-1648.
37. Lembreghts M, Ansseau M. 1993. Les marqueurs biologiques dans ls schizophrénies, Encéphale 19:501-523.
38. Maes ME, Bosmans G, Kenis R, De Jong R, Smith S, Meltzer HY. 1997. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 26:221-225.
39. Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. 2000. The immune system and schizophrenia: an integrative view. In: Conti A, Maestroni G, McCann S, Sternberg E, Lipton J, Smith C, editors. Neuroimmunomodulation. New York: New York Academy of Science. p 456.
40. Murphy S, Pearce B, Morrow C. 1986. Astrocytes have both M1 and M2 muscarinic receptor sutypes. Brain Res 364:177-180.
41. Niizato K, Iritani S, et al. 2001. Astrogial function of schizophrenic brain: a study using lobotomized brain. Neuroreport 12:1457-1460.
42. Noy S, Achiron A, Laor N. 1994. Schizophrenia and autoimmunity a possible etiological mechanism? Neuropsychobiol 30:157-159.
43. Overall JE, Gorham DR. 1962. Brief psychiatric rating scale. Psychol Rep 10:799-812.
44. Pandey RS, Gupta AK, Chaturvedi VC. 1981. Autoimmune model of schizophrenia with special reference to anti-brain antibodies. Biol Psychiatry 16:1123-1136.
45. Radewicz K, Garey LJ, Gentleman SM, Reynolds R. 2000. Increase HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59:137-150.
46. Rajkowska G, Halaris A, Selemon LD. 2001. Reductions in neuronal and glial density characterize th dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49:741-752.
47. Rapaport HM, McAllister CG, Pickar D, Nelson DL, Paul SM. 1989. Elevated levels of soluble interleukin-2 receptors in schizophrenia. Arch Gen Psychiatry 46:291-292.
48. Schubert P, Morino T, Miyazaki H, Ogata T, Nakamura Y, Marchini C, Ferroni S. 2000. Cascade glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann NY Acad Sci 903:24-33.
49. Shintani F, Kanba S, Marou N, Nakaki T, Nibuya M, Suzuki E, Kinoshita N, Yagi G. 1991. Serum interleukin-6 in schizophrenic patients. Life Sci 49:661-664.
50. Spitzer RL, Williams JB, Gibbon M. 1991. Manual for the structured clinical interview for DSM-II-R with psychotic screen. Washington, DC: American Psychiatric Press.
51. Suvisaari J, Haukka J, Tanskanen A, Hovi T, Lonnqvist J. 1999. Association between prenatal exposure to poliovirus infection and adult schizophrenia. Am J Psychiatry 156:1100-1102.
52. Tandon R, Greden JF. 1989. Cholinergic hyperactivity and negative schizophrenic symptoms: a model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46:745-753.
53. Tandon R. 1999. Cholinergic aspects of schizophrenia. Br J Psychiatry 174:7-11.
54. Vartanian ME, Kolyaskina GI, Lozovsky DV, Burbaeva GS, Ignatov SA. 1978. Aspects of humoral and cellular immunity in schizophrenia. Birth Defects 14:339-364.
55. Webster MJ, Knable MB, Johnston-Wilson N, Nagata K, Inagaki M, Yolken RH. 2001. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder and depression. Brain Behav Immun 15:388-400.
56. Westergaard T, Mortensen PB, Pedersen CB, Wohlfahrt J, Melbye M. 1999. Exposure to prenatal and childhood infections and the risk of schizophrenia: suggestions from a study of sibship characteristics and influenza prevalence. Arch Gen Psychiatry 56:993-998.
57. Yeomans JS. 1992. Mesopontine cholinergic cells and mesolimbic dopamine functions, including schizophrenia. Soc Neurosci 18:911.
58. Yeomans JS. 1995. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharm 12:3-16.
59. Zameer A, Hoffman SA. 2001. Immunoglobulin binding to brain in autoimmune mice. J Neuroimmunol 120:10-18.